159 related articles for article (PubMed ID: 18294844)
21. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors.
Suzuki N; Suzuki T; Ota Y; Nakano T; Kurihara M; Okuda H; Yamori T; Tsumoto H; Nakagawa H; Miyata N
J Med Chem; 2009 May; 52(9):2909-22. PubMed ID: 19419205
[TBL] [Abstract][Full Text] [Related]
22. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
[TBL] [Abstract][Full Text] [Related]
23. Molecular basis of histone deacetylase inhibitors as new drugs for the treatment of inflammatory diseases and cancer.
Glauben R; Siegmund B
Methods Mol Biol; 2009; 512():365-76. PubMed ID: 19347289
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.
Charrier C; Clarhaut J; Gesson JP; Estiu G; Wiest O; Roche J; Bertrand P
J Med Chem; 2009 May; 52(9):3112-5. PubMed ID: 19385600
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic resuscitation: cell protective mechanisms of histone deacetylase inhibition in lethal hemorrhagic shock.
Butt MU; Sailhamer EA; Li Y; Liu B; Shuja F; Velmahos GC; DeMoya M; King DR; Alam HB
J Surg Res; 2009 Oct; 156(2):290-6. PubMed ID: 19665733
[TBL] [Abstract][Full Text] [Related]
26. Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.
Angibaud P; Arts J; Van Emelen K; Poncelet V; Pilatte I; Roux B; Van Brandt S; Verdonck M; De Winter H; Ten Holte P; Marien A; Floren W; Janssens B; Van Dun J; Aerts A; Van Gompel J; Gaurrand S; Queguiner L; Argoullon JM; Van Hijfte L; Freyne E; Janicot M
Eur J Med Chem; 2005 Jun; 40(6):597-606. PubMed ID: 15922843
[TBL] [Abstract][Full Text] [Related]
27. Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies.
Bora-Tatar G; Dayangaç-Erden D; Demir AS; Dalkara S; Yelekçi K; Erdem-Yurter H
Bioorg Med Chem; 2009 Jul; 17(14):5219-28. PubMed ID: 19520580
[TBL] [Abstract][Full Text] [Related]
28. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines.
Catalano MG; Poli R; Pugliese M; Fortunati N; Boccuzzi G
Endocr Relat Cancer; 2007 Sep; 14(3):839-45. PubMed ID: 17914112
[TBL] [Abstract][Full Text] [Related]
29. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.
Armeanu S; Pathil A; Venturelli S; Mascagni P; Weiss TS; Göttlicher M; Gregor M; Lauer UM; Bitzer M
J Hepatol; 2005 Feb; 42(2):210-7. PubMed ID: 15664246
[TBL] [Abstract][Full Text] [Related]
30. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib.
Catalano MG; Pugliese M; Poli R; Bosco O; Bertieri R; Fortunati N; Boccuzzi G
Oncol Rep; 2009 Feb; 21(2):515-21. PubMed ID: 19148530
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
Kim HM; Lee K; Park BW; Ryu DK; Kim K; Lee CW; Park SK; Han JW; Lee HY; Lee HY; Han G
Bioorg Med Chem Lett; 2006 Aug; 16(15):4068-70. PubMed ID: 16723227
[TBL] [Abstract][Full Text] [Related]
32. [A new target of cancer therapy: advances in the study of histone deacetylase].
Liu AL; Long J; Wang N; Du GH
Yao Xue Xue Bao; 2005 Jul; 40(7):585-90. PubMed ID: 16196262
[No Abstract] [Full Text] [Related]
33. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
34. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors.
Stapnes C; Ryningen A; Hatfield K; Øyan AM; Eide GE; Corbascio M; Kalland KH; Gjertsen BT; Bruserud Ø
Int J Oncol; 2007 Dec; 31(6):1529-38. PubMed ID: 17982680
[TBL] [Abstract][Full Text] [Related]
35. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo.
Sami S; Höti N; Xu HM; Shen Z; Huang X
J Biochem; 2008 Sep; 144(3):357-62. PubMed ID: 18515856
[TBL] [Abstract][Full Text] [Related]
36. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.
Blaheta RA; Michaelis M; Driever PH; Cinatl J
Med Res Rev; 2005 Jul; 25(4):383-97. PubMed ID: 15637697
[TBL] [Abstract][Full Text] [Related]
37. Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Kim TH; Yoo YH; Kang DY; Suh H; Park MK; Park KJ; Kim SH
Int J Oncol; 2009 May; 34(5):1353-62. PubMed ID: 19360347
[TBL] [Abstract][Full Text] [Related]
38. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations.
Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955
[TBL] [Abstract][Full Text] [Related]
39. Boric acid inhibits embryonic histone deacetylases: a suggested mechanism to explain boric acid-related teratogenicity.
Di Renzo F; Cappelletti G; Broccia ML; Giavini E; Menegola E
Toxicol Appl Pharmacol; 2007 Apr; 220(2):178-85. PubMed ID: 17320131
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.
Suzuki T; Ando T; Tsuchiya K; Fukazawa N; Saito A; Mariko Y; Yamashita T; Nakanishi O
J Med Chem; 1999 Jul; 42(15):3001-3. PubMed ID: 10425110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
